Monographie - Ceftolozane / tazobactam - Stabilis 4.0

Viimane versioon :
08/05/2024

Antibiootikum

Ceftolozane / tazobactam

Süsteravim

Stabiilsus lahustes

Stabiilsust mõjutavad tegurid

Stabiilsust mõjutavad faktorid

Sobimatus

Manustamis viis

Viited

Pdf

Keemiline struktuur

Kaubanduslikud nimed erinevates maades

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Zepilen	Hispaania
Zerbaxa	Ameerika ühendriigid, Argentiina, Ecuador, Hispaania, Maroko, Mehhiko, Prantsusmaa, Rumeenia, Saksamaa, Suurbritannia, Sveits, Tšiili

Viited

Süsteravim

Viited : Ceftolozane / tazobactam

	Tüüp	Avaldamine
3520	Labor	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Labor	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Labor	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Labor	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3803	Labor	Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics Laboratoires Merck Sharp & Dohme Chibret 2020
3827	Plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3984	Ajaleht	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	Ajaleht	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Ajaleht	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4378	Ajaleht	Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 2020 ; 40, 5: 470-476.
4434	Ajaleht	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Ajaleht	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Ajaleht	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4645	Ajaleht	Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C. Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist 2021
4801	Ajaleht	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales